Aradigm Corporation and CyDex, Inc. Sign Development Collaboration Agreement

HAYWARD, Calif. & LENEXA, Kan.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) and CyDex, Inc. (“CyDex”) today announced they have entered into a two-year Collaboration Agreement (the “Agreement”) for the development and commercialization of combination products containing inhaled corticosteroids, anticholinergics and beta-2 agonists for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).